1. An improved assay fo cyclic 3′:5′-nucleotide phosphodiesterases with QAE-sephadex columns;BAUER;Naunyn Schmiedebergs Arch. Pharmacol,1980
2. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors;BEAVO;Trends Pharmacol. Sci,1990
3. Differential antagonism by 1,3-Dipropylxanthine-8-cyclopentylxanthine and 9-chloro-2-(2-furanyl)-5,6-dihydro-1,2,4-triazolo(1,5-c)quinazolin-5-imine of the effects of adenosine derivatives in the presence of isoprenaline on contractile response and cyclic AMP content in cardiomyocytes. Evidence for the coexistence of A1 and A2 adenosine receptors on cardiomyocytes;BEHNKE;J. Pharmacol. Exp. Ther,1990
4. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts;BETHKE;Naunyn Schmiedebergs Arch. Pharamcol,1988
5. Effects of enoximone and isomazole on force of contraction and phosphodiesterase activity in human myocardial tissue;BETHKE;Naunyn Schmiedebergs Arch. Pharmacol,1989